ABU-DHABI-SECURITIES
14.1.2020 18:05:11 CET | Business Wire | Press release
ADX is participating in the "Second Abu Dhabi Sustainable Finance Forum" held under the umbrella of "Abu Dhabi Sustainability Week 2020", one of the world's most prominent sustainability events which takes place in the capital Abu Dhabi from 11th to 18th of January 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200114005680/en/
ADX is one of the signatories of the "Abu Dhabi Sustainable Finance Declaration", and a member of the "United Nations Sustainable Stock Exchange Initiative" (SSE). Today, Abu Dhabi Securities Exchange (ADX) announced that it will issue its first Environmental, Social & Governance (ESG) report in the first half of 2020. The report will be issued annually and is the first of its kind in the region.
The announcement comes few months after ADX issued a set of ESG disclosure guidelines to encourage listed companies to follow its lead and incorporate ESG issues into their business to test their effectiveness and act upon it. This will encourage listed companies to issue their sustainability reports, and it illustrates ADX’s commitment to drive sustainability in financial markets.
ADX is looking forward to an active participation in the discussions of the forum, which serves as an important opportunity to meet with different leaders around the world. ADX will discuss ways to integrate sustainability within the regulatory frameworks of investment institutions and cooperation with local and international sector leaders. This will enhance communication, knowledge and awareness in the field of sustainable financing, and will also help to explore Current and future opportunities for both sustainable finance and capital investment sectors, to obtain positive economic, social and environmental outcomes.
H.E. Khalifa Salem Al Mansouri, Chief Executive of ADX , said: “One of ADX’s strategic objectives is to advance Sustainable Development Goals (SDGs) through Sustainable Finance. Today I am proud to announce that ADX will release its first annual Environmental, Social & Governance (ESG) report in the first half of 2020. The report is instrumental in advancing our Sustainable Finance Agenda and promoting high sustainability standards. It also marks a significative step towards enhancing ADX's competitiveness and attracting more sustainable investments to Abu Dhabi.”
His Excellency continued: "In line with the growing investments made to companies that implements environmental, social and corporate governance, we aim to develop and position ADX as a vibrant and thriving sustainable investment hub that supports capital formation, raising and deployment as well as the creation and issuance of products to achieve positive economic, social and environmental objectives.”
His Excellency added: “Companies' commitments to developing strategies that integrate the standards of the report opens the way for investments supported by US$83 Trillion from various Asset Management Funds (AMC). These funds will be directed to companies that apply environmental, social and corporate governance standards. New Financial instruments and policies are among the instrumental components that will make up sustainable finance and ADX’s ESG report will encourage the business community to adopt practices that achieve environmental and social sustainability standards."
By adopting these high standards, ADX is in harmony with “Towards the next 50” that charts out the UAE’s strategic development plan which aims to build a sustainable, diversified and high value-added economy that positively contributes to transition to a new global sustainable development paradigm. ADX’s ESG report reinforces the guiding principles on Sustainable Finance and encourages building up investment opportunities while increasing the quality and depth of sustainable investments in the UAE.
About Abu Dhabi Securities Exchange:
Abu Dhabi Securities Exchange (ADX) was established on November 15 of the year 2000 by Local Law No. (3) Of 2000, the provisions of which vest the market with a legal entity of autonomous status, independent finance and management. The Law also provides ADX with the necessary supervisory and executive powers to exercise its functions.
ADX is a market for trading securities; including shares issued by public joint stock companies, bonds issued by governments or corporations, exchange traded funds, and any other financial instruments approved by the UAE Securities and Commodities Authority (SCA).
In 2014, ADX was upgraded to ‘Emerging Market’ status by both MSCI and S&P Dow Jones. ADX was already classified as an Emerging Market by FTSE in 2009 and in 2011 by S&P and Russell Investments.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005680/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom